Deciphera Pharmaceuticals — Technical Presentation (September 2019)
18 slides from Deciphera Pharmaceuticals's technical presentation, Sep 30, 2019
Slide 1: INVICTUS: Phase 3 Study of Ripretinib as ≥4th Line Therapy in GIST
Margaret von Mehren, Steven Attia, Sebastian Bauer, Ping Chi, Gina D’Amato, Suzanne George, Hans Gelderblom, Michael C. Heinrich, Robin L. Jones, Peter Reichardt, Patrick Schoffski, Cesar Serrano, John Zalcberg, Julie Meade, Kelvin Shi, Rodrigo Ruiz-Soto, Jean-Yves Blay INVICTUS: A Phase 3, INterVen
Slide 2: Acknowledgements
Acknowledgements We would like to thank the patients and their families and caregivers, the investigators, and the investigational site staff of the INVICTUS study. Each flag corresponds to the participating country and the number of participating centers within that country.
Slide 3: Disclosures
Disclosures Margaret von Mehren: advisory/consultancy role with Deciphera Pharmaceuticals, LLC, Blueprint MedicinesTM Corporation, and Exelixis, Inc.; travel accommodations from Deciphera Pharmaceuticals, LLC and the National Comprehensive Cancer Network®; institutional supportive research funding f
Slide 4: KIT Mutations Drive ~80% of GIST
KIT Mutations Drive ~80% of GIST GIST is a rare sarcoma accounting for 1% to 2% of GI malignancies1 Primary mutations in KIT or PDGFRA occur in >85% of patients with GIST2 Mutations lead to activation of the kinase3 1. Parab TM, et al. J Gastrointest Oncol. 2019;10:144-154. 2. Hsueh YS, et al. PLOS
Slide 5: GIST Current Treatment Landscape
GIST Current Treatment Landscape Line of Therapy 1st line 2nd line 3rd line 4th line Current approved therapy Imatinib Sunitinib Regorafenib No approved therapy Median PFS Imatinib 400 mg: 20.4 mo1a Imatinib 800 mg: 24.0 mo1a P=0.18 Sunitinib: 5.6 mo2b Placebo: 1.4 mo2b P<0.0001 Regorafenib: 4.8 mo3
Slide 6: Ripretinib Mechanism of Action
Ripretinib Mechanism of Action Ripretinib is a novel tyrosine kinase switch control inhibitor engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a unique dual mechanism of action that regulates the kinase switch pocket and activation loop Smith BD, et al. Cancer Cell. 2019;35:738-
Slide 7: INVICTUS: Randomized Phase 3 Study Design
Objective response rate (ORR) assessed by BICR (Key endpoint) Overall survival (OS) INVICTUS: Randomized Phase 3 Study Design Evaluated ripretinib as ≥4th line therapy in patients with advanced GIST Primary endpoint PFS (per modified RECIST based on Blinded Independent Central Review [BICR]) Select
Slide 8: Patient Disposition
Patient Disposition Receiving ripretinib at cutoff (n=36) Receiving ripretinib at cutoff (n=11) Receiving placebo at cutoff (n=1) Eligibility assessed (n=154) Screen failures (n=25) Randomized (ITT population) (n=129) Ripretinib (double-blind period) (n=85) Placebo (double-blind period) (n=44) Disco
Slide 9: Baseline Characteristics
Baseline Characteristics Ripretinib (n=85) Placebo (n=44) Total (n=129) Age (years) Median (min, max) 59 (29, 82) 65 (33, 83) 60 (29, 83) 18–64 years 57 (67%) 22 (50%) 79 (61%) 65–74 years 20 (24%) 12 (27%) 32 (25%) ≥ 75 years 8 (9%) 10 (23%) 18 (14%) Gender Male (%) 47 (55%) 26 (59%) 73 (57%) Race
Slide 10: 85% Risk Reduction of Disease Progression or Death With Ripretinib Compared With Placebo
85% Risk Reduction of Disease Progression or Death With Ripretinib Compared With Placebo *Double-blind period. Ripretinib (n=85) Placebo (n=44) Events, n (%) 51 (60.0%) 37 (84.1%) Censored, n (%) 34 (40.0%) 7 (15.9%) PFS 6 months, % (95% CI) 51.0% (39.4–61.4) 3.2% (0.2–13.8) 100 80 60 40 20 0 0 2 4
Slide 11: Ripretinib Showed PFS Benefit in All Assessed Patient Subgroups
Ripretinib Showed PFS Benefit in All Assessed Patient Subgroups In favor of ripretinib In favor of placebo
Slide 12: Durable Response With Ripretinib
Median duration of response has not been reached yet *7 of 8 ripretinib responders are still responding as of data cutoff All responders had partial responses Durable Response With Ripretinib ORR 9.4% Confirmed ORR (n=8) ORR 0% (n=0) Ripretinib (n=85) Placebo (n=44) P=0.0504 Patients Who Responded (
Slide 13: OS Benefit: 64% Risk Reduction of Death Compared With Placebo
OS Benefit: 64% Risk Reduction of Death Compared With Placebo *Due to hierarchal testing procedures of the end points, the OS end point could not be formally tested because the ORR was not statistically significant. Ripretinib (n=85) Placebo (n=44) Events, n (%) 26 (30.6%) 26 (59.1%) Censored, n (%)
Slide 14: Crossover Provided OS Benefit
Crossover Provided OS Benefit Median OS (months) 95% CI Ripretinib 15.1 (12.3–15.1) Placebo patients with crossover 11.6 (6.3–NE) Placebo patients without crossover 1.8 (0.9–4.9) 100 80 60 40 20 0 0 4 6 8 10 16 Months Survival probability (%) 85 29 15 Ripretinib Placebo patients with crossover Place
Slide 15: TEAEs in >10% of Patients
TEAEs in >10% of Patients Preferred Term Ripretinib any grade (n=85) Placebo any grade (n=43)* Any TEAE or grade 3/4 TEAE** 84 (98.8%) 42 (97.7%) Alopecia 44 (51.8%) 2 (4.7%) Fatigue 36 (42.4%) 10 (23.3%) Nausea 33 (38.8%) 5 (11.6%) Abdominal pain 31 (36.5%) 13 (30.2%) Constipation 29 (34.1%) 8 (18.
Slide 16: TEAEs in >10% of Patients
*44 patients were randomized to placebo, but 1 did not receive treatment. **Regardless of causality TEAEs in >10% of Patients Preferred Term Ripretinib any grade (n=85) Placebo any grade (n=43)* Any TEAE or grade 3/4 TEAE** 84 (98.8%) 42 (97.7%) Alopecia 44 (51.8%) 2 (4.7%) Fatigue 36 (42.4%) 10 (23
Slide 17: TEAE Leading to Dose Modification
TEAE Leading to Dose Modification *44 patients were randomized to placebo, but one did not receive treatment. **One patient in each arm considered possibly related to blinded study drug Categories n (%) Ripretinib (n=85) Placebo (n=43)* Any TEAE leading to dose reduction 6 (7.1%) 1 (2.3%) Any TEAE l
Slide 18: INVICTUS: Conclusions
INVICTUS: Conclusions Median PFS was significantly improved with ripretinib compared with placebo (6.3 vs 1.0 months; HR=0.15 [95% CI, 0.09–0.25]) Risk of progression or death reduced by 85% compared with placebo Median OS with ripretinib was 15.1 months vs 6.6 months in the placebo arm (HR=0.36 [95
Deciphera Pharmaceuticals — Technical Presentation (September 2019) on 6ix